| scholarly article | Q13442814 |
| P50 | author | Albert J Czaja | Q87649280 |
| P2860 | cites work | Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications | Q24669577 |
| Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome | Q27860719 | ||
| Chronic thyroiditis and autoimmunization | Q28181381 | ||
| A "NEW" ANTIGEN IN LEUKEMIA SERA | Q28201325 | ||
| Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis | Q28248157 | ||
| Histological grading and staging of chronic hepatitis | Q29619625 | ||
| International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis | Q33784003 | ||
| Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors | Q34094790 | ||
| Diagnosis and management of autoimmune hepatitis | Q34118165 | ||
| Association of autoimmune active chronic hepatitis with HL-A1,8. | Q34202251 | ||
| Adrenal cortical metabolism in chronic liver disease | Q75676837 | ||
| THE COURSE AND TREATMENT OF LUPOID HEPATITIS | Q76505450 | ||
| Hepatitis complicated by manifestations of lupus erythematosus | Q78335144 | ||
| Hepatitis and cirrhosis in women with positive clot tests for lupus erythematosus | Q78435938 | ||
| Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus | Q78519760 | ||
| Local formation of gamma-globulin in the diseased liver, and its relation to hepatic necrosis | Q79047099 | ||
| Chronic liver disease in young people. Clinical features and course in thirty-three patients | Q79108157 | ||
| A sheep in wolf's clothing | Q79333119 | ||
| A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1 | Q79671071 | ||
| Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis | Q79798205 | ||
| Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse | Q79825440 | ||
| Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly | Q82640069 | ||
| Performance parameters of the conventional serological markers for autoimmune hepatitis | Q82719034 | ||
| British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis | Q84561367 | ||
| EASL Clinical Practice Guidelines: Autoimmune hepatitis | Q86075911 | ||
| Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis | Q91818978 | ||
| "Lupoid" hepatitis, a nonentity in the spectrum of chronic active liver disease | Q93728181 | ||
| Controlled trial of prednisone and azathioprine in active chronic hepatitis | Q93735616 | ||
| Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease | Q34408786 | ||
| Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis BS antigen | Q34472161 | ||
| Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared | Q34477263 | ||
| ACTIVE 'JUVENILE' CIRRHOSIS CONSIDERED AS PART OF A SYSTEMIC DISEASE AND THE EFFECT OF CORTICOSTEROID THERAPY | Q34478010 | ||
| Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. | Q36185465 | ||
| Autoimmune Hepatitis: Focusing on Treatments other than Steroids | Q36231841 | ||
| The validity and importance of subtypes in autoimmune hepatitis: a point of view | Q36690069 | ||
| The variant forms of autoimmune hepatitis | Q36820820 | ||
| Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy | Q37075975 | ||
| B-Cell Activating Factor Belonging to the Tumor Necrosis Factor Family and Interferon-γ-Inducible Protein-10 in Autoimmune Hepatitis | Q37205477 | ||
| Auto-immune chronic active hepatitis: a specific entity? The negative argument | Q37804844 | ||
| Drug-Induced Autoimmune-Like Hepatitis | Q37843783 | ||
| Autoantibody-Negative Autoimmune Hepatitis | Q37970311 | ||
| Drug choices in autoimmune hepatitis: Part B – nonsteroids | Q38051706 | ||
| Acute and Acute Severe (Fulminant) Autoimmune Hepatitis | Q38054513 | ||
| Cirrhosis of the liver: a reversible disease? | Q38070373 | ||
| Autoimmune hepatitis in diverse ethnic populations and geographical regions | Q38103631 | ||
| Cholestatic phenotypes of autoimmune hepatitis | Q38135212 | ||
| Transitioning from Idiopathic to Explainable Autoimmune Hepatitis | Q38496935 | ||
| Evolving paradigm of treatment for autoimmune hepatitis | Q38730872 | ||
| HLA Determinants in Chronic Active Liver Disease: Possible Relation of HLA-Dw3 to Prognosis | Q39430301 | ||
| Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis | Q39436336 | ||
| The nature of piecemeal necrosis in chronic active hepatitis | Q39568933 | ||
| Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis | Q40044046 | ||
| Drug-induced chronic liver disease, with emphasis on chronic active hepatitis | Q40337719 | ||
| Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance | Q40402510 | ||
| Features and Progression of Asymptomatic Autoimmune Hepatitis in Italy | Q40717973 | ||
| Classification of chronic hepatitis: diagnosis, grading and staging | Q40755087 | ||
| The spectrum of liver disease in systemic lupus erythematosus | Q41034596 | ||
| HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. | Q41544167 | ||
| Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis | Q42285314 | ||
| Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis | Q42369219 | ||
| The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine | Q42557814 | ||
| Immunocytochemical study of gamma globulin in liver in hepatitis and postnecrotic cirrhosis | Q42825273 | ||
| Hepatitis C virus replication in 'autoimmune' chronic hepatitis | Q42986051 | ||
| Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis | Q42989153 | ||
| Virus-induced autoimmunity in hepatitis C virus infections: a rare event | Q43035417 | ||
| Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis | Q43036529 | ||
| Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States | Q43048900 | ||
| Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. | Q43050091 | ||
| Recurrent autoimmune hepatitis after orthotopic liver transplantation | Q43575678 | ||
| Use of corticosteroid therapy in autoimmune hepatitis resulting in the resolution of cirrhosis | Q43586384 | ||
| Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy | Q43586395 | ||
| Autoimmune Hepatitis: The Dilemma of Rare Diseases | Q43837229 | ||
| Drug-induced active chronic hepatitis | Q43937011 | ||
| Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis | Q44086661 | ||
| Simplified criteria for the diagnosis of autoimmune hepatitis | Q44425899 | ||
| Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? | Q45257325 | ||
| Presumed cryptogenic liver disease in Germany: High prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology | Q47873026 | ||
| Epigenetic changes and their implications in autoimmune hepatitis. | Q49565965 | ||
| Reversal of cirrhosis: evidence-based medicine? | Q50582672 | ||
| Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. | Q50585755 | ||
| Prognosis of histological cirrhosis in type 1 autoimmune hepatitis | Q51035941 | ||
| The nature and prognosis of severe cryptogenic chronic active hepatitis | Q51052985 | ||
| Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. | Q52641231 | ||
| Performance parameters of the diagnostic scoring systems for autoimmune hepatitis | Q53207120 | ||
| Autoimmune hepatitis in childhood: a 20-year experience | Q53361457 | ||
| "Where are the gnomes of yesteryear?". | Q53433794 | ||
| Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin | Q53686594 | ||
| Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis | Q53888400 | ||
| Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1 | Q56968434 | ||
| Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management | Q57177957 | ||
| Recurrent and de novo autoimmune hepatitis | Q58097060 | ||
| Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis | Q58108351 | ||
| Is autoimmune chronic active hepatitis a HCV-related disease? | Q58803543 | ||
| Chronic hepatitis--a perspective on classification and determinants of prognosis | Q67782698 | ||
| Type 2 autoimmune hepatitis and hepatitis C virus infection | Q68082887 | ||
| How lupoid is lupoid hepatitis? | Q69494810 | ||
| Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen | Q69893348 | ||
| HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis | Q69980447 | ||
| Prognosis of chronic persistent hepatitis | Q70125160 | ||
| Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting | Q70335757 | ||
| Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution | Q70379977 | ||
| Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy | Q70642501 | ||
| Concept of autoimmune disease | Q70886240 | ||
| Smooth muscle autoantibody in "autoimmune" hepatitis | Q71191938 | ||
| Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis | Q71373108 | ||
| Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis | Q71428816 | ||
| Classification and treatment of chronic active liver disease | Q72234048 | ||
| Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis | Q73191758 | ||
| Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis | Q73404019 | ||
| Reversibility of Hepatic Fibrosis in Autoimmune Hepatitis | Q73976726 | ||
| The problem of chronic liver disease in young women | Q74130027 | ||
| De-novo autoimmune hepatitis after liver transplantation | Q74242368 | ||
| Lupoid hepatitis | Q74334969 | ||
| Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis | Q74637187 | ||
| P433 | issue | Suppl 1 | |
| P921 | main subject | autoimmune hepatitis | Q786844 |
| P304 | page(s) | S72-S81 | |
| P577 | publication date | 2020-02-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Clinical liver disease | Q27726171 |
| P1476 | title | Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination | |
| P478 | volume | 15 |
Search more.